Big biotech, Big pharma, Biotech, Partnering

Celgene and Zymeworks partner for bi-specific antibody therapeutics

Posted on 22 January 2015

Tags: , , ,

Zymeworks announced a collaboration and licensing agreement with Celgene for the research, development, and commercialization of bi-specific antibody therapeutics enabled using Zymeworks’ proprietary Azymetric platform.

Zymeworks and Celgene will collaborate on the research and development of multiple bi-specific antibodies based on the Azymetric platform.

Celgene will have the option to advance the resulting bi-specific candidates through clinical development and subsequent commercialization.

Searching for more deal information? Current Partnering offers the following options:

  • CP Reports | Browse titles | Over 200 report titles that focus upon different deal types from licensing, co-promotion to distribution, biomarkers to drug delivery, oncology to psychiatry, all of which provide you with an insight into the latest life science deal making trends
  • Current Agreements | Login | Find out more | Updated daily by our industry analysts, our fully searchable life sciences intelligence database allows you to find deals and alliances dating as far back as 2000 saving you valuable time on your deal making research activities
  • CP Knowledge Centre | Login | Find out more | Provides you with an all-in-one intelligence package that allows you to simultaneously access our CP reports, CP Insight and Current Agreements deal and alliances database, at the same time

 

Zymeworks will receive an initial upfront payment, as well as an equity investment from Celgene.

Zymeworks is eligible to receive clinical, regulatory, and commercial milestones on successful candidates totaling up to US $164M per therapeutic candidate.

Additionally, Zymeworks will receive royalties on worldwide net sales.

Further financial details are not disclosed.

For further deal information visit Current Agreements (subscription required)

Related

Scorecard: Top partnering deals by value in 2014

View: Top pharmaceutical companies

View: Top biotech companies

Reports: Browse our extensive deal making report portfolio

Print Friendly, PDF & Email

Leave a Reply